Wall Street analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to announce earnings of ($1.26) per share for the current quarter, Zacks reports. Five analysts have issued estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.37) to ($1.12). Wave Life Sciences posted earnings per share of ($1.09) during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.6%. The business is expected to report its next earnings results on Monday, March 11th.

On average, analysts expect that Wave Life Sciences will report full year earnings of ($4.99) per share for the current fiscal year, with EPS estimates ranging from ($5.21) to ($4.66). For the next financial year, analysts forecast that the firm will report earnings of ($2.88) per share, with EPS estimates ranging from ($5.03) to ($1.13). Zacks’ EPS averages are an average based on a survey of research analysts that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Friday, November 9th. The company reported ($1.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.26) by ($0.02). The company had revenue of $4.49 million for the quarter, compared to the consensus estimate of $5.36 million. Wave Life Sciences had a negative net margin of 1,114.49% and a negative return on equity of 107.14%.

Several equities analysts have recently commented on the company. HC Wainwright set a $49.00 target price on Wave Life Sciences and gave the company a “buy” rating in a report on Monday. BidaskClub raised Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. Mizuho set a $65.00 target price on Wave Life Sciences and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Stifel Nicolaus assumed coverage on Wave Life Sciences in a report on Monday, August 6th. They set a “buy” rating and a $56.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $58.40.

In related news, VP Chandra Vargeese sold 3,000 shares of the stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $55.00, for a total value of $165,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chris Francis sold 11,575 shares of the stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $56.00, for a total value of $648,200.00. The disclosure for this sale can be found here. Insiders have sold 44,075 shares of company stock valued at $2,435,700 over the last ninety days. Corporate insiders own 44.20% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new position in Wave Life Sciences in the 3rd quarter worth approximately $140,000. United Services Automobile Association bought a new position in Wave Life Sciences in the 3rd quarter worth approximately $204,000. California Public Employees Retirement System bought a new position in Wave Life Sciences in the 1st quarter worth approximately $219,000. Voya Investment Management LLC grew its holdings in Wave Life Sciences by 37.8% in the 2nd quarter. Voya Investment Management LLC now owns 6,873 shares of the company’s stock worth $263,000 after buying an additional 1,884 shares in the last quarter. Finally, Millennium Management LLC bought a new position in Wave Life Sciences in the 1st quarter worth approximately $330,000. 83.46% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:WVE traded down $0.61 during trading on Tuesday, hitting $39.06. 65,000 shares of the company traded hands, compared to its average volume of 162,006. The firm has a market capitalization of $1.27 billion, a PE ratio of -10.15 and a beta of 1.10. Wave Life Sciences has a one year low of $23.07 and a one year high of $56.00. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.05.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Read More: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.